Allogene Therapeutics, Inc. 

CA

  SEC # 1737287

        

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

Registrant
 SEC-Registered:  4/12/18   —   First EDGAR Filing:  4/19/18   –   Last Filing:  4/26/24 

Business Address      On:  4/26/24       [ Map ]		Mailing Address      On:  4/26/24       [ Map ]
210 East Grand Avenue South San Francisco, California  94080 U.S.A.

Phone #		Organized In		Fiscal-Year End		IRS #		SEC CIK		SEC File #
+1 650-457-2700		Delaware, U.S.A.		12/31/yy		82-3562771		0001737287		001-38693

Market: Symbol:  Nasdaq: ALLO

— Common Stock

In Major Indexes:	S&P Total Market — NASDAQ Composite — Russell 2000  &  Russell 3000

Industry Classification

GICS – Global Industry Classification Standard:        Sector      →    Sub-Industry   Health Care Biotechnology   ICB – Industry Classification Benchmark:               Industry    →       Subsector      Health Care Biotechnology   SIC:     Code      U.S. Industry      Through      Source      Filings-Review Office 2836 Biological Products, Except Diagnostic Substances 2024 SEC Office of Life Sciences

        

Management
Director   In   CA   Belldegrun Arie 2018-2024   CA   Chang David D 2018-2024   NY   Humer Franz B 2018-2023   NY   Kazam Joshua A 2018-2023   CA   Messemer Deborah M. 2018-2023   CA   Witte Owen N. 2018-2023   Barrett Elizabeth A. 2021-2023   MA   Sato Vicki L 2021-2023   NJ   Mayo Stephen 2022-2023   TX   Bonderman David 2018-2020 ↓List Pre-2020 Directors				Officer  Since  Most-Recent Title   In   TN   Douglas Earl Martin 2023 SVP, General Counsel 2024   CA   Moore Timothy L. 2023 Chief Technical Officer 2024   CA   Parker Geoffrey M. 2023 Chief Financial Officer 2024   TX   Roberts Zachary 2023 EVP of R&D 2024   CA   Chang David D 2018 President & CEO 2024   CA   Chen Yinlin Jack SVP, Finance 2023   CA   Smith Lillian VP, Corporate Counsel 2023   CA   Bhavnagri Veer 2020 General Counsel 2023   CA   Moore Alison 2018 Chief Technical Officer 2023   CA   Schmidt Eric Thomas 2018 Chief Financial Officer 2023   CA   Amado Rafael 2019 EVP of R&D 2022

        

        

        

        

Securities
Market:  Symbol    Description        (Prices) (Type — Name)   Nasdaq:  ALLO   Common Stock — COM _________  Symbol source:  SEC  As of:  4/25/24		CUSIP, CINS or PPN       Description ← Symbol   Issuer Issue (Class or re: Filing — Name)      To 2024:   019770 019770·10·6     Common — COM ← ALLO 019770·01·5     Options _________  Classes source:  Form 13F Filings that list Section 13(f) Securities